Bio-Path (NASDAQ:BPTH) Coverage Initiated by Analysts at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTHGet Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.

Bio-Path Stock Performance

Shares of NASDAQ:BPTH opened at $0.82 on Wednesday. The stock’s fifty day simple moving average is $0.89 and its two-hundred day simple moving average is $1.07. Bio-Path has a 1-year low of $0.59 and a 1-year high of $9.99.

About Bio-Path

(Get Free Report)

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Further Reading

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.